Optimizing ALK-TKI Sequencing and Neurological Outcomes

, , ,

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss the circumstances under which they would consider switching patients on different first-line treatments to lorlatinib and outline approaches for CNS surveillance and management in ALK-positive patients.

  1. For patients already on different first-line treatment, under what circumstances would you consider switching them to lorlatinib?
  2. How should we approach CNS surveillance and management in ALK-positive patients?

Related Content:

Future Directions in ALK-Positive and BRAF-Positive NSCLC Management
Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC
Long-Term Outcomes of BRAF-MEK Inhibitor Combinations